Profire Energy As An Investment Versus A Trade

Profire Energy (PFIE)

Profire Energy, Inc. (OTCBB: PFIE) in the last month has traded down from $0.90 since the Company reported record financial results on November 14, 2011 to roughly $0.75 in the last few days.

Why is Profire Energy (PFIE) down?

Earnings and Growing Revenues – Back in November, PFIE reported record income before tax for the 9/30/11 quarter ending of $1,646,575 on total revenues of $4.5 million. Revenues have more than doubled in comparison to the previous year revenues of $2.2 million, and it has NO DEBT! For the six month period, Profire reported $7.2 million in sales and $2.7 million EBT. How many times do Small-Cap investors hear about “next quarter”? Profire is delivering now.

The Product – Burner Management Systems (BMS): Profire is filling many voids in the safety and efficiency of upstream pipeline flow of oil and gas, while helping the industry reduce its carbon footprint.  Several models have been developed over the last decade, with Profire’s latest model, the 2100 BMS, steadily grabbing more and more market share. With its electronic ignition and series of sensors, the flame is only lit when the pipeline requires, saving countless amounts of fuel and greatly reducing emissions. Any problems with ignition or the unit are remotely relayed, saving manpower and money. Moreover, torches are no longer required, eliminating the risk or injury to employees.

Growth Plans - Again the Investor Presentation speaks to growth in the U.S., France, Brazil, and “many other countries.”

Management Team – I don’t know the management team personally, so I simply say let’s judge them on their results and that takes us back to the last quarter’s financials which were very good.

Industry – Oil and gas is high growth, high demand industry with numerous stakeholders.  Given the strong balance sheet, revenues and earnings, PFIE seems like a viable option without the risk that comes along with small producers. For existing wells with relatively known production metrics the PFIE units can increase production and improve margins by utilizing their technologies. With increasing energy regulation coming out of Washington, (right or wrong, it is there) Profire is positioned to help companies meet the new energy and regulatory demand.

So why is Profire Energy potentially undervalued? Simply stated, Profire Energy is not well known outside their small niche of the world, and now Management is beginning to reach out to investors to tell their story.

The good news: It is a story based on numbers rather than a “story”.

The bad news: Investors will ALWAYS buy earnings per share, and PFIE may not be hidden for long.

Profire Energy (PFIE) Stock Quote and News:

Disclaimer: Neither nor its officers, directors, partners, employees or anyone involved in the publication of the website or newsletters (“us” or “we”) is a registered investment adviser or licensed broker-dealer in any jurisdiction whatsoever. Further, we are not qualified to provide any investment advice and we make no recommendation to purchase or sell any securities. The prior article is published as information only for our readers. is a third party publisher of news and research. Our site does not make recommendations, but offers information portals to research news, articles, stock lists and recent research. Nothing on our site should be construed as an offer or solicitation to buy or sell products or securities. This site is sometimes compensated by featured companies, news submissions and online advertising. Viper Enterprises, LLC (parent company of OTC Showcase) has been compensated twenty-six thousand dollars for one month of consultation and journalism services and to manage a comprehensive investor relations/awareness program by Profire Energy Inc. Please read and fully understand our entire disclaimer at


Add your comment

Commenting is allowed only for registered users.

Other articlesgo to homepage

Stocks Mixed on Monday

Stocks Mixed on Monday(0)

The Dow Jones industrial average topped 16,000 for the first time ever Monday, while the S&P 500 briefly surpassed 1,800. The Dow retreated from the 16,000 level, but still gained 14.32 points from Friday”s all-time high close, to 15,976. The S&P 500 index dipped 6.65 points to 1,791.53. The NASDAQ fell 36.90 points to 3,949.07

Cellceutix Targeting Gram-Negative and Candida Fungal Infections

Cellceutix Targeting Gram-Negative and Candida Fungal Infections(0)

Monday morning, Cellceutix Corp. (OTCQB: CTIX) provided shareholders with an update on its progress with filing an Investigational New Drug application with the FDA for its anti-psoriasis drug. Additionally – and taking the headline – the company delivered to shareholders news that it has made additional promising advancements with its pipeline to potentially address diseases

Catalyst Pharmaceutical Partners Stock Chart Analysis Video

Catalyst Pharmaceutical Partners Stock Chart Analysis Video(0)

The Catalyst Pharmaceutical Partners (NASDAQ: CPRX) stock chart formed a piercing line reversal pattern on Wednesday and Thursday that was confirmed with a sharp move upwards on Friday. Technical traders will be watching support around the 200 day moving average at $1.25 on any pullback, but for the time being, the chart looks to be

EnteroMedics Stock Chart Analysis Video

EnteroMedics Stock Chart Analysis Video(0)

The EnteroMedics (NASDAQ:ETRM) chart has been making higher highs and higher lows since forming a double bottom early in the year. The chart is holding over the 50-day moving average and inching higher each day as it tries to gain momentum to make the next leg up in the channel. EnteroMedics is a medical device

NXT-ID Authentication Using Face and Voice Recognition

NXT-ID Authentication Using Face and Voice Recognition(0)

There’s a Wocket in My Pocket! may soon not just be a sentence from the mouths of children after reading the rhyming book by Dr. Seuss. There was plenty of made-up ridiculousness in the iconic book, such as a bofa on the sofa, but there is nothing fictitious about the Wocket, a next-generation payment and

read more

Stay Informed

Receive the OTCS Newsletter *


* required

Dana-Farber to Host Cellceutix Trials

Cellceutix Corporation (CTIX)
Cellceutix Corporation has filed its Investigational New Drug application with the FDA. Dana-Farber and Beth Israel Deaconess Medical Center will be hosting the clinical trials for Kevetrin, Cellceutix's novel cancer drug. Read more news and get a stock quote.

Diabetes Rate Growing Exponentially

According to the International Diabetes Federation, more than 500 million people will be diagnosed with diabetes in the next two decades, a more than 50 percent increase from today. Technologies are available presently to help manage the frequency, complications and costs associated with diabetes. Read the complete article to learn more.

Contacts and information

Have an opinion or news that you want to share?

Social networks

Most popular categories

© 2011 Viper Enterprises, LLC. All rights reserved.